Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Arthur Riggs Diabetes & Metabolism Research Institute
CONTACT
Lead
City of Hope Medical Center
With
This is a single-center, pilot clinical trial of autologous CD6-targeted chimeric antigen receptor regulatory T cells (autoCD6-CAR Tregs) in patients diagnosed with Type 1 Diabetes (T1D). This study is designed to evaluate the safety, tolerability, and feasibility of autoCD6-CAR Tregs as T1D treatment. Currently, the disease is managed through intensive supportive care. Patients require multiple daily injections or continuous pump delivery of exogenous insulin therapy to manage blood glucose levels. Furthermore, chronic hyperglycemia and hyperglycemic excursions increase the risk of both acute and chronic complications, which can be life-threatening (e.g., severe hypoglycemia, ketoacidosis leading to coma, retinopathy, neuropathy, and nephropathy). Therefore, there is an urgent unmet medical need for curative therapies for patients with T1D. We propose to harness the natural immunomodulatory capacity of regulatory T cells (Tregs) to specifically target pathogenic autoreactive effector T cells (Teffs). CD6 has been implicated in several autoimmune diseases and is highly expressed by activated Teff cells whereas Tregs express little or no CD6. Itolizumab is a first-in-class humanized anti-CD6 monoclonal antibody (mAb) with demonstrated clinical efficacy in psoriasis. Our therapeutic approach is to co-opt the chimeric antigen receptor (CAR) T cell platform to generate autologous Tregs expressing a CD6-targeting CAR (autoCD6-CAR Tregs), which are expected to target activated pathogenic T cells while sparing Tregs in T1D patients.
Age
18–35
Sex
ALL
Healthy volunteers
Not accepted
